Clinical Trials in Marburg, Germany

56 recruiting

Showing 120 of 75 trials

Recruiting
Phase 2

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca1,160 enrolled363 locationsNCT07082738
Recruiting
Phase 2

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Colorectal Cancer Stage IIIColorectal Cancer Stage II
BioNTech SE327 enrolled121 locationsNCT04486378
Recruiting
Phase 3

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma
Bristol-Myers Squibb1,216 enrolled285 locationsNCT05827016
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled217 locationsNCT06170788
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled239 locationsNCT06459180
Recruiting
Phase 1Phase 2

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Leukemia RelapseLymphoma Diffuse Large B-cellLeukemia and Lymphoma+1 more
AvenCell Therapeutics, Inc.178 enrolled6 locationsNCT07284433
Recruiting
Phase 3

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Endometrial Cancer
AstraZeneca600 enrolled249 locationsNCT06989112
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Parkinson's Disease
Boston Scientific Corporation1,500 enrolled84 locationsNCT02071134
Recruiting

PROCARE - PROstate Cancer Real World Evidence Registry

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)+2 more
UroTrials Company (GmbH)5,000 enrolled53 locationsNCT06835218
Recruiting
Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 2Phase 3

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
AbbVie430 enrolled53 locationsNCT07155187
Recruiting
Phase 3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled320 locationsNCT06136650
Recruiting
Phase 3

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric CancerGastroesophageal-junction Cancer
AstraZeneca572 enrolled186 locationsNCT06346392
Recruiting
Not Applicable

Glioblastoma Radiotherapy Using IMRT or Proton Beams

Glioblastoma
University Hospital Heidelberg326 enrolled3 locationsNCT04752280
Recruiting

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals800 enrolled111 locationsNCT05344469
Recruiting
Phase 3

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled280 locationsNCT06561386
Recruiting
Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis
Sanofi1,600 enrolled386 locationsNCT06141473
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca990 enrolled297 locationsNCT06883305